![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan (H.Y., M.N., T.F., H.S., A.N., M.K., T.Y.); and Department of Legal Medicine, Iwate Medical University School of Medicine, Morioka, Japan (M.T., Y.A.)
Nornicotine is an N-demethylated metabolite of nicotine. In the present study, human cytochrome P450 (P450) isoform(s) involved in nicotine N-demethylation were identified. The Eadie-Hofstee plot of nicotine N-demethylation in human liver microsomes was biphasic with high-affinity (apparent Km = 173 ± 70 µM, Vmax = 57 ± 17 pmol/min/mg) and low-affinity (apparent Km = 619 ± 68 µM, Vmax = 137 ± 6 pmol/min/mg) components. Among 13 recombinant human P450s expressed in baculovirus-infected insect cells (Supersomes), CYP2B6 exhibited the highest nicotine N-demethylase activity, followed by CYP2A6. The apparent Km values of CYP2A6 (49 ± 12 µM) and CYP2B6 (550 ± 46 µM) were close to those of high- and low-affinity components in human liver microsomes, respectively. The intrinsic clearances of CYP2A6 and CYP2B6 Supersomes were 5.1 and 12.5 nl/min/pmol P450, respectively. In addition, the intrinsic clearance of CYP2A13 expressed in Escherichia coli (44.9 nl/min/pmol P450) was higher than that of CYP2A6 expressed in E. coli (2.6 nl/min/pmol P450). Since CYP2A13 is hardly expressed in human livers, the contribution of CYP2A13 to the nicotine N-demethylation in human liver microsomes would be negligible. The nicotine N-demethylase activity in microsomes from 15 human livers at 20 µM nicotine was significantly correlated with the CYP2A6 contents (r = 0.578, p < 0.05), coumarin 7-hydroxylase activity (r = 0.802, p < 0.001), and S-mephenytoin N-demethylase activity (r = 0.694, p < 0.005). The nicotine N-demethylase activity at 100 µM nicotine was significantly correlated with the CYP2B6 contents (r = 0.677, p < 0.05) and S-mephenytoin N-demethylase activities (r = 0.740, p < 0.005). These results as well as the inhibition analyses suggested that CYP2A6 and CYP2B6 would significantly contribute to the nicotine N-demethylation at low and high substrate concentrations, respectively. The contributions of CYP2A6 and CYP2B6 would be dependent on the expression levels of these isoforms in any human liver.
This article has been cited by other articles:
![]() |
S. Ben-Zaken Cohen, P. D. Pare, S. F. P. Man, and D. D. Sin The Growing Burden of Chronic Obstructive Pulmonary Disease and Lung Cancer in Women: Examining Sex Differences in Cigarette Smoke Metabolism Am. J. Respir. Crit. Care Med., July 15, 2007; 176(2): 113 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Higashi, M. Nakajima, M. Katoh, S. Tokudome, and T. Yokoi Inhibitory Effects of Neurotransmitters and Steroids on Human CYP2A6 Drug Metab. Dispos., April 1, 2007; 35(4): 508 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fukami, M. Nakajima, H. Sakai, M. Katoh, and T. Yokoi CYP2A13 Metabolizes the Substrates of Human CYP1A2, Phenacetin, and Theophylline Drug Metab. Dispos., March 1, 2007; 35(3): 335 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shebley, M. I. Jushchyshyn, and P. F. Hollenberg SELECTIVE PATHWAYS FOR THE METABOLISM OF PHENCYCLIDINE BY CYTOCHROME P450 2B ENZYMES: IDENTIFICATION OF ELECTROPHILIC METABOLITES, GLUTATHIONE, AND N-ACETYL CYSTEINE ADDUCTS Drug Metab. Dispos., March 1, 2006; 34(3): 375 - 383. [Abstract] [Full Text] [PDF] |
||||